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LCOCABASTINE is an extremely potent and highly
selective HI-receptor antagonist which has been
specifically developed as eye drops and nasal
spray for the treatment of allergic rhino-
conjunctivitis. Clinical experience to date
suggests that this topical antihistamine is at least
as effective as other cm-nt first-line therapeutic
approaches for the treatment of this condition,
including oral Hi-receptor antagonists and
sodium cromoglycate. Onset of action is rapid,
with clinical effects apparent within minutes of
instillation. Moreover, duration of action is suffi-
ciently long to permit a convenient twice-daily
dosing regimen. Topical levocabastine is well tol-
erated with an adverse-effect profile comparable
with that of placebo and sodium cromoglycate.
As might be expected from the route of drug
administration, application site reactions are the
most frequent adverse effect associated with levo-
cabastine eye drops and nasal spray with an inci-
dence comparable with that seen in placebo-
treated controls. The availability of effective and
well-tolerated topical antihistamines, such as
levocabastine, is an important advance which
broadens the range of therapeutic approaches
available for the clinical management of allergic
rhinoconjunctivitis. Levocabastine appears to be
an attractive alternative to oral antihistamines as
a first-line therapeutic option for the treatment of
this atopic condition.
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Epidemiology and Aim of Therapy
Mlergic rhinoconjunctivitis is a common atopic
condition which is frequently encountered in
clinical practice, with current estimates suggesting
that as many as 22% of the general population
may be affected. Available epidemiological data
suggest that the incidence of this atopic disorder
12 is increasing,’ particularly in urban areas, possi-
2-4 bly as a result of environmental pollution. The
relationship between air pollution and the pre-
valence of allergic disease is, however, complex.
Analysis of the prevalence of respiratory diseases
and atopic disorders in German children has
revealed that the prevalence of allergic disorders
was lower in the former East Germany than in
West Germany in spite of higher pollution
levels.5 Characteristic clinical manifestations
include nasal itching, sneezing, rhinorrhoea and
congestion, often accompanied by ocular symp-
toms of lacrimation, redness and itching. Causa-
tive allergens are diverse and include grass, tree
and weed pollens, fungal spores, house dust mite
and animal dander.
The medical and socioeconomic impact of
allergic rhinoconjunctivitis is often under-
estimated. Although rarely associated with long-
term clinical complications, symptoms may be
sufficiently severe to impact on the patient’s
quality of life, with almost all patients experienc-
ing a degree of sleep impairment, limitation of
normal daily activities and emotional distress.
6
These findings are supported by data from the
US Department of Health which reveal that aller-
gic rhinoconjunctivitis accounts for more than 2
million lost school days and 3.5 million lost work
days every year in the USA alone.
7
Treatment of allergic rhinoconjunctivitis should
not only be aimed at direct amelioration of
symptoms. The subsequent inflammation after
allergen exposure may induce non-specific
hyperreactivity and nasal priming.’9 Reduction of
this inflammation may therefore be expected to
interrupt the vicious circle of early and late
sequelae of allergen exposure, including nasal
hyperreactivity. Indeed, it has been demonstrated
that treatment of the nose may have a beneficial
effect on lung function and bronchial hyper-
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responsiveness in patients with concurrent a number of advantages over an orally adminis-
asthma.1’11 tered drug, including a faster onset of action,
The fundamental approach to the treatment of since it is applied directly to the affected site, and
allergic rhinoconjunctivitis is environmental a reduced potential for systemic adverse effects.
control, combined with appropriate antiallergic Until recently, however, topical administration of
drug therapy and, in selected cases, specific Hi-receptor antagonists has not been feasible as
immunotherapy. Levocabastine is a novel H1- the available agents have not been sufficiently
receptor antagonist which has been specifically potent to permit single agent therapy. Topical
developed for the topical treatment of allergic treatment for allergic rhinoconjunctivitis was
rhinoconjunctivitis. The aim of this paper is to therefore limited to sodium cromoglycate, vaso-
review the clinical experience of this topical anti- constrictors and corticosteroids.
histamine available to date, with particular refer- The mast cell stabilizer, sodium cromoglycate,
ence to the implications for patient management, is both effective and well tolerated for the pro-
phylaxis of allergic rhinoconjunctivitis. However,
it has a slow onset of action and may take several Pathophysiology: the Role of Histamine days to achieve full therapeutic effects. As a
Our understanding of the pathophysiology of result, treatment should preferably be initiated
allergic rhinoconjunctivitis has increased con- prior to allergen exposure and maintenance
siderably in recent years revealing a number of therapy is essential in patients with frequent
potential targets for pharmacological intervention, symptoms. As sodium cromoglycate requires fre-
Therapeutic approaches available for the clinical quent instillation, sometimes as often as six times
management of this atopic condition include H1- daily, patient compliance with a long-term main-
receptor antagonists, vasoconstrictors, cortico- tenance regimen is likely to be problematic.
steroids, and mast cell stabilizers, such as sodium Like sodium cromoglycate, topical vasocon-
cromoglycate. Although multiple inflammatory strictor and antihistamine/vasoconstrictor combi-
mediators have been implicated in the pathogen- nations are also limited by the need for frequent
esis of allergic rhinoconjunctivitis, histamine instillation. Furthermore, although these topical
appears to play a prominent role.
12 Experimental preparations provide rapid wmptomatic relief,
allergen challenge studies have revealed that his- they are only suitable for short-term use. Long-
tamine is the only mediator which produces the term administration is associated with rebound
full spectrum of clinical manifestations of the vasodilatation which may result in rhinitis and
acute allergic reaction when applied to the nasal conjunctivitis medicamentosa. 17’18 These agents
and ocular mucosa. The available pathophysio- should, therefore, generally not be used for more
logical evidence therefore supports the current than 5 to 7 days consecutively.
clinical practice for use of Hi-receptor antago- Topical corticosteroids are highly effective anti-
nists as a primary treatment option.1 inflammatory agents, however they also have a
The efficacy and tolerability of oral anti- slow onset of action, typically taking several days
histamines in the treatment of allergic rhino- to achieve full therapeutic effects. Conse-
conjunctivitis is well documented..14 However, quently, these agents are most effective when
although the reported incidence of adverse reac- administered prophylactically and treatment
tions such as sedation is minimal with newer should preferably be initiated prior to the onset
drugs of this class, the potential for unwanted of symptoms for maximum clinical benefit. Fur-
systemic effects, as exemplified by the arrhythmic thermore, while intranasal corticosteroids are
effects seen with certain oral antihistamines, generally well tolerated and the risk of suppres-
clearly exists.5 In addition, as might be expected sion of the hypothalamic-pituitary-adrenal axis
from the route of drug administration, onset of is low following topical application of these
action with oral antihistamines is relatively slow. drugs, long-term ocular administration should
Peak antihistaminic activity ils4 typically not generally be avoided due to the potential for
observed for several hours, necessitating serious adverse effects including glaucoma, catar-
administration prior to allergen exposure for acts and severe corneal infections.9
maximum clinical benefit. Two topical antihistamine preparations are
now available for the treatment of allergic rhino-
Rationale for Topical Therapy conjunctivitis, levocabastine and azelastine. Levo-
cabastine is an extremely potent and highly
Treatment for allergic rhinoconjunctivitis need selective H-receptor antagonist which has been
not necessarily be systemic. Topical therapy is specifically developed as eye drops and nasal
possible due to the accessibility of the affected spray for the topical treatment of allergic rhino-
20 21 tissues. A topical agent may be expected to have conjunctivitis. Azelastine appears to possess
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other anti-allergic properties in addition to its
antihistaminic activity which may be of benefit to
patients with this atopic condition, but is cur-
rently only available as a nasal spray necessitating
combination therapy with other anti-allergic
agents in patients with concurrent ocular symp-
toms.
The Efficacy of Levocabastine in Adults
Levocabastine is the most potent antihistamine
available to date, expressing antihistaminic activ-
ity at doses lower than 0.002 mg/kg, with in vitro
data derived from the compound 48/80 lethality
test in rats suggesting that it is 15 000 times more
potent than chlorpheniramine and 1000 times
more potent than azelastine.22’23 Levocabastine
has a highly specific binding affinity for H-
receptors, with no evidence of anticholinergic
activity at doses considerably in excess of thera-
peutic concentrations. Detailed pharmacokinetic
analysis demonstrates that levocabastine is well
suited to the topical treatment of allergic rhino-
conjunctivitis, with the clinical benefits seen with
this agent being predominantly mediated by local
antihistaminic effects in the ocular and nasal
mucosa.24,25
Histamine and allergen challenge studies have
shown that levocabastine is a potent inhibitor of
the allergic response in the human eye and
nose.26-3 Onset of action is rapid, with sig-
nifican symptomatic relief _typically seen within
28 3o minutes of administration. Duration of action
is sufficiently long to permit a convenient twice
daily dosing schedule.2
A comprehensive programme of clinical trials
has been undertaken to assess the therapeutic
efficacy of topical levocabastine for the treatment
of allergic rhinoconjunctivitis in adults. Key find-
ings from studies published to date are summar-
ized below.
Levocabastine and oral antihistamines: A
number of clinical trials have assessed the com-
parative efficacy of levocabastine and second-
generation oral antihistamines. Levocabastine eye
drops (0.5 mg/ml: one drop in each eye twice
daily) and nasal spray (0.5 mg/ml: two puffs in
each nostril twice daily) have been shown to be
at least as effective as oral terfenadine (60 mg
twice daily) for the treatment of seasonal allergic
rhinoconjunctivitis in double-blind studies invol-
ving more than 350 patients to date. A number
of statistically significant differences in favour of
the topical antihistamine have also been reported
in some trials.34’35 Patient evaluations after 8
weeks of treatment have shown that the effect of
therapy on ocular symptoms was excellent or
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FIG. 1. Percentages of patients reporting excellent or good
global therapeutic efficacy for ocular and nasal symptoms after 8
weeks of treatment with topical levocabastine or oral terfena-
dine.
33 Reproduced with the kind permission of Blackwell Scien-
tific Publishers, London, UK.
good in 80% of levocabastine-treated patients
compared with 73% in those who received terfe-
nadine, with the effect of therapy on nasal symp-
toms being excellent or good in 62% and 61% of
patients in the two groups, respectively (Fig. 1).33
Similarly, twice daily treatment with levocabas-
tine eye drops and nasal spray has been shown
to be at least as effective as oral loratadine (10
mg) once daily in a recent double-blind, primary
care based trial involving 95 patients with sea-
sonal allergic rhinoconjunctivitis.6 A non-sig-
nifican trend in favour of the topical anti-
histamine was apparent at the end of the 5-week
treatment period, with an excellent or good
response to therapy observed in 86% of levoca-
bastine-treated patients compared with 77% for
those who received loratadine.
As a double-dummy technique was used in
these trials to blind study medication, patients
treated with oral H-receptor antagonists also
received placebo eye drops and nasal spray.
Response rates as high as 73% have been asso-
ciated with the use of topical placebos,7 which
may have contributed in part to the clinical ben-
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FIG. 2. Onset of action for nasal and ocular symptoms in patients receiving levocabastine
nasal spray or oral cetirizine.
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efits seen in patients on oral antihistamines in
these trials. Consequently, in order to obtain a
more realistic assessment of the comparative effi-
cacy of topical and oral antihistamine therapy, an
open-label, randomized trial has recently been
undertaken to compare the effects of twice daily
treatments with levocabastine nasal spray, with
eye drops on demand, with once daily oral cetir-
izine (10 mg) in more than 200 patients with
rhn n unc 8 perennial allergic "oco tivitis. Treatment
duration was 2 weeks.
As might be expected from the route of drug
administration, onset of action was found to be
significantly more rapid in patients treated with
topical levocabastine than in those who received
oral cetirizine (p < 0.001). In all, 36% of levoca-
bastine-treated patients reported relief from nasal
symptoms within 15 min of drug administration
compared with 10% of those on cetirizine. Cor-
responding values for ocular symptoms were
32% and 17% in the two groups, respectively, at
this time (Fig. 2). Therapeutic efficacy was gen-
erally found to be comparable in the two treat-
ment groups, with no statistically significant
intergroup differences reported during the
course of the trial. In all, 61% of levocabastine-
treated patients rated global therapeutic efficacy
to be excellent or good compared with 62% on
cetirizine.
Levocabastine and azelastine: The comparative
efficacy of levocabastine nasal spray (0.5 mg/ml,
two puffs per nostril twice daily) and topical aze-
lastine (1 mg/ml, one puff per nostril twice daily)
in the treatment of allergic rhinitis has been eval-
uated in a total of 242 patients in an open-label,
randomized trial.39 Treatment duration was 1
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week. Onset of action was found to be compar-
able for the two topical antihistamines, with over
50% of patients in each group reporting sig-
nificant relief from symptoms within 30 min of
study drug administration. In general, therapeutic
efficacy was also similar in the two treatment
groups with a comparable reduction in the sever-
ity of all symptoms, including nasal congestion,
seen in both treatment groups. Assessments of
global therapeutic efficacy revealed a non-sig-
nificant trend in favour of levocabastine, with the
effect of treatment considered to be excellent or
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FIG. 3. Percentages of patients reporting excellent or good
global therapeutic efficacy after week of treatment with levo-
cabastine or azelastine.
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good in 70% of patients who received levocabas-
tine compared with 63% of those on azelastine
(Fig. 3).
Levocabastine and topical corticosteroids: Twice
daily treatment with levocabastine eye drops and
nasal spray appears to be as effective as twice
daily flunisolide nasal spray for the treatment of
nasal symptoms of allergic rhinoconjunctivitis,
according to the results of a randomized, paral-
lel-group, single-blind study involving a total of
66 patients.
4 At the end of the 1 month treat-
ment period, response to therapy was found to
be excellent or good in 53% of levocabastine-
treated patients compared with 64% of those
who received the topical corticosteroid (N.S.). In
this study, corticosteroid-treated patients also
received naphazoline/antazoline eye drops four
times daily. Levocabastine was found to provide
significantly greater relief from concurrent ocular
symptoms than this vasoconstrictor/antihistamine
combination, with an excellent or good response
to therapy reported in 47% and 19% of patients
in the two groups, respectively, at the end of the
trial (p < 0.05).
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r] Levocabastine
6 Beclomethasone dipropionate
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symptoms congestion and
rhinorrhoea
FIG. 4. Mean total symptom scores (0 absent to 7 severe) at
baseline and after treatment with levocabastine nasal spray for 2
weeks followed by beclomethasone dipropionate nasal spray for
45 2 weeks, p < 0.05; **p < 0.001 versus baseline. Repro-
duced with the kind permission of Munksgaard Int. Publishers
Ltd, Copenhagen, Denmark.
It is well documented that oral antihistamines
are generally less effective than topical cortico-
steroids for the relief of nasal congestion.41’42
This is not surprising as other mediators such as
kinins, prostaglandin D2 and leukotrienes C4 and
D4 are also known to increase nasal airway resis-
tance.43’44 In order to assess whether combina-
tion therapy with an intranasal steroid could
provide additional clinical benefit to that seen
with a topical antihistamine alone, the efficacy of
beclomethasone diproprionate nasal spray was
evaluated as add-on therapy in a double-blind
trial in 44 patients with allergic rhinitis who were
already receiving intranasal levocabastine.45 As
might be expected, the severity of nasal conges-
tion was found to be significantly lower in
patients receiving both agents (p < 0.001),
however, combination therapy was not associated
with any additional improvement in the severity
of other symptoms of allergic rhinitis compared
with that seen with levocabastine alone (Fig. 4).
Levocabastine and sodium cromoglycate: Levoca-
bastine eye drops and nasal spray appear to be
Levocabastine
-1 Sodium cromoglycate
100-,
90 r-- --I
Ocular Nasal
symptoms symptoms
FIG. 5. Percentages of patients reporting excellent or good
global therapeutic efficacy after 2 weeks of topical treatment
with levocabastine or sodium cromoglycate.
46-49 Reproduced
with permission.
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significantly more effective for the treatment of those who have received levocabastine eye
allergic rhinoconjunctivitis than topical therapy drops. This compares with incidences of 4% and
with sodium cromoglycate (Fig. 5). To date, two 15% for topical placebos, and 5% and 16% for
double-blind trials, involving a total of 114 sodium cromoglycate nasal spray and eye drops,
patients with allergic rhinitis, have been pub- respectively.
lished which compare the efficacy of levocabas- Levocabastine appears to be better tolerated
tine nasal spray (0.5 mg/ml; two puffs per nostril than azelastine. Results of the only comparative
four times daily) with that of intranasal sodium study of levocabastine and azelastine undertaken
cromoglycate (20 mg/ml; two puffs per nostril to date reveal significantly higher incidences of
four times daily).46’47 In both trials, levocabastine application site reactions and taste disturbances
was found to be significantly more effective than in azelastine-treated patients than in those who
sodium cromoglycate at the end of the 2-week received levocabastine (5% versus 1%; p < 0.05,
treatment period, with an excellent or good and 5% versus 0%; p < 0.01, respectively).9
response to therapy seen in 76% and 46% of Levocabastine also appears to be better tolerated
patients in the two groups, respectively (p < than other topical therapeutic approaches, with
0.01). Levocabastine eye drops (0.5 mg/ml; one local irritation following administration reported
drop in each eye twice daily) also appear to in up to 36% of patients receiving the vasocon-
provide significantly greater relief from symptoms strictor/antihistamine eye drops naphazoline/
of allergic conjunctivitis than ocular sodium cro- antazoline, and 25% of those treated with the
moglycate (20 mg/ml; one drop in each eye four intranasal steroid flunisolide.
4
times daily). In two double-blind, placebo-con- Long-term ocular administration of levocabas-
trolled studies involving a total of 158 patients, tine appears to be well tolerated, with compre-
an excellent or good response to therapy was hensive ophthalmological examinations in
observed in 87% of levocabastine-treated patients patients receiving levocabastine eye drops reveal-
compared with 78% in those who received ing no serious adverse effects to date.5 Similarly,
sodium cromoglycate (p < 0.05).48’49 there has been no evidence of tachyphylaxis or
rebound in patients receiving levocabastine eye
drops, to date, with treatment durations of up to The Efficacy of Levocabastine in Children 4 months.54
The therapeutic efficacy of topical levocabas- In addition, it is important that a nasal spray
tine for the treatment of allergic rhinoconjunctivi- should not affect ciliary function. The effects of
tis in paediatric patients has been assessed in levocabastine nasal spray on ciliary function have
studies involving more than 300 children and a been studied in vitro on human adenoid tissue
comprehensive review of the role of topical anti- and in vivo in healthy volunteers. Levocabastine
histamine therapy in this patient population has was not found to affect either ciliary beat fre-
been published.
5 Clinical experience, to date, quency or mucociliary transit time suggesting that
suggests that topical levocabastine is at least as ciliotoxicity during long-term intranasal adminis-
effective and well tolerated as the current first- tration is extremely unlikely.
55
line therapy for the treatment of allergic rhino-
conjunctivitis in children, sodium cromoglycate, The Role of Levocabastine both as monotherapy or in combination with
oral antihistamines, with a number of statistically An understanding of the immunological events
significant differences in therapeutic efficacy in during and after allergen exposure is necessary
favour of the topical antihistamine reported in for the optimal clinical management of allergic
the largest of these trials.5 rhinoconjunctivitis. As in bronchial asthma, a
step-wise approach to therapy appears to be
Tolerability indicated depending on symptom frequency and
severity.
Levocabastine eye drops and nasal spray The basic approachin the clinicalmanagement
appear to be well tolerated with an adverse effect of any allergic disorder is environmental control.
profile comparable with that seen with sodium Following identification of the causative allergen,
cromoglycate or placebo.
52 As might be expected measures to reduce allergen exposure and
from the route of drug administration, applica- appropriate patient education are essential.
tion site reactions are the most frequent adverse However, in many patients, complete allergen
effect associated with topical levocabastine. In avoidance may be difficult to achieve. Specific
large scale clinical trials, local irritation following immunotherapy may also be beneficial if the cau-
application has been reported in 3% of patients sative allergen is well defined, especially in mod-
treated withlevocabastine nasal sprayand 14% of erate to severe pollen allergy, however the
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individual response to therapy with other aller-
gens is highly variable. Consequently, almost all
patients with allergic rhinoconjunctivitis will also
require appropriate anti-allergic medication.
The wide range of pharmacological ap-
proaches available for the clinical management of
allergic rhinoconjunctivitis enables treatment to
be individualized according to patient needs.
Oral H-receptor antagonists are generally con-
sidered as first-line therapy due to the central
role of histamine H-mediated effects in the
pathogenesis of this allergic condition. 12’13
However, a potent topical antihistamine with a
Occasional symptoms
Allergen avoidance
Treatment with an antihistamine with a
rapid onset of action, such as
levocabastine eye drops and nasal spray,
if contact with the allergen cannot be
avoided.
Moderate daily symptoms
Allergen avoidance
Immunotherapy if required
Treatment with topical or oral
antihistamines.
Alternatively maintenance therapy with
sodium cromoglycate.
Add intranasal steroid for nasal
symptoms if required.
Severe daily symptoms
Allergen avoidance
Immunotherapy if required
Combination therapy with topical or
oral antihistamine plus steroid nasal spray.
A short course of oral steroids may be
required for the control of breakthrough
symptoms.
FIG. 6. Proposed algorithm for the treatment of allergic rhino-
conjunctivitis.
rapid onset of action, such as levocabastine, may
be a more appropriate therapeutic choice.
Topical levocabastine appears to be at least as
effective as oral antihistamines for the treatment
of allergic rhinoconjunctivitis, with the advan-
tage of a significantly more rapid onset of
action8 and, in particular, may provide greater
relief from symptoms on days with high pollen
counts.56 Furthermore, topical levocabastine is at
least as effective as azelastine nasal spray, with
the advantage of a more favourable tolerability
profile and the availability of eye dro9Ps
for the
relief of concurrent ocular symptoms.
It is well documented that nasal congestion is
generally less responsive to treatment with HI-
receptor antagonists than other symptoms of
allergic rhinoconjunctivitis.41’42 Mthough pre-
liminary data suggest that topical levocabastine
may provide more effective relief from nasal
symptoms than oral antihistamine therapy,4’5
concurrent treatment with an intranasal steroid,
or a topical or oral decongestant, may be indi-
cated in patients with more severe daily symp-
toms, particularly if nasal congestion is
predominant. The available data suggest that
addition of an intranasal steroid provides sig-
nificantl greater relief from nasal congestion
than treatment with levocabastine nasal spray
alone.45
Sodium cromoglycate is often considered as a
primary treatment option for the treatment of
allergic rhinoconjunctivitis in children due to its
excellent adverse-effect profile. Results from pae-
diatric trials suggest that levocabastine may be a
more appropriate first-line therapy in this patient
population being significantly more effective and
as well tolerated.5’5
A proposed algorithm for the treatment of
allergic rhinoconjunctivitis is shown in Fig. 6. It is
apparent that the availability of an effective and
well-tolerated topical antihistamine, such as levo-
cabastine, is an important advance which broad-
ens the range of therapeutic approaches available
for the clinical management of allergic rhino-
conjunctivitis. Clinical evidence available to date
suggests that levocabastine is an attractive alter-
native to oral antihistamines and that this topical
antihistamine should be considered as a first-line
therapeutic option for the treatment of this
atopic condition.
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